Skip to main content
Log in

French Economic Evaluations of Influenza and Influenza Vaccination

  • Section 3: Economic Evaluation of Influenza Vaccination and Economic Modelling
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

The cost-of-illness studies of influenza performed in France for the years 1985 and 1989 have shown that the major economic consideration is the respective sizes of indirect and direct costs.

Depending on the point of view (from the perspective of National Health Insurance or the societal perspective) and the method used for measuring indirect costs, it was estimated that they could be between 1.5 and 9 times higher than direct costs.

A cost-benefit study of influenza vaccination for the employed adult population showed that vaccination is a cost-saving strategy, although this was also contingent upon the problems associated with measuring indirect benefits as well as the effectiveness rate of vaccination in real conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lévy E, Lafarge H. L’evaluation du cout de la grippe dans la France contemporaine. April 1987: 41 (unpublished report)

  2. Ministere de la Solidarite de la Sante et de la Protection Sociale Enquete de Morbidite Hospitaliere 1985-87. Fichessynthetiques par pathologies, in documents statistiques du SESI no. 89, mail, 1990

  3. Drummond M. Cost of illness studies. A major headache? Pharmacoeconomics 1992; 2 (1): 1–4

    Article  PubMed  CAS  Google Scholar 

  4. Hodgson TA. Cost of illness on cost effectiveness analysis: a review of the methodology. Pharmacoeconomics 1994; 6 (6): 536–52

    Article  PubMed  CAS  Google Scholar 

  5. Lafarge H, Levy P. Deux evaluations du cout de la grippe. 1990: 25 (unpublished report)

  6. Caisse Nationale d’Assurance Maladie des Travailleurs Salaries. Statistoques mensuelles. Resultats a fin Fevrier

  7. Levy E, Levy P. La vaccination contre la grippe des personnes d’age actif (25-65 ans): une etude cout–benefice. Rev Epidemet Sante Publ 1992; 40: 285–95

    CAS  Google Scholar 

  8. Levy E. A cost–benefit study of influenza vaccination for 25 to 64 year old French people. In: Hannoun C, Kendal AP, Klenk HD, editors. Options for the control of influenza II. Amsterdam: Elsevier Science Publishing: 1993

    Google Scholar 

  9. Merlin M, Buisson Y. L’evaluation de l’efficacite de la vaccination antigrippale dans les armees au cours de l’hiver 1989-90,1990; BEH: 41

  10. Les Comptes de la Nation 1989, INSEE, Paris: 1990

  11. Couet C. Bilan demographique 1994,58 million d’inhabitants in INSEE Premiere no. 359; Paris, Fevrier: 1995

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levy, E. French Economic Evaluations of Influenza and Influenza Vaccination. Pharmacoeconomics 9 (Suppl 3), 62–66 (1996). https://doi.org/10.2165/00019053-199600093-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199600093-00014

Keywords

Navigation